文献速递妇科肿瘤

多塔利单抗治疗复发性或晚期错配修复缺陷子宫内膜癌的临床活性与安全性

Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial.
PubMed 文献 · JAMA Oncol · 2020-01-01

这项正在进行的开放标签、单组、多中心1期研究纳入104例错配修复缺陷子宫内膜癌女性,其中71例可评估疗效。确认的客观缓解率为42.3%(95%CI 30.6%-54.6%),完全缓解9例(12.7%),部分缓解21例(29.6%)。缓解持久,中位缓解持续时间未达到,6个月和12个月维持缓解的估计概率分别为96.4%和76.8%。

要点

  • 多塔利单抗在经铂类化疗后的dMMR子宫内膜癌中客观缓解率达42.3%。
  • 缓解持久,12个月维持缓解概率为76.8%。
  • 常见≥3级治疗相关不良事件为贫血、结肠炎和腹泻。

核心结论

  • 在非随机试验中,多塔利单抗对经铂类化疗后的错配修复缺陷子宫内膜癌显示出有临床意义且持久的抗肿瘤活性,安全性可接受。

研究设计与样本

  • 正在进行的开放标签、单组、多中心1期研究,2016年3月7日开始第一部分,2017年5月8日开始入组错配修复缺陷子宫内膜癌患者。
  • 共104例女性患者接受多塔利单抗治疗,中位年龄64.0岁(范围38-80岁),中位随访11.2个月(范围0.03至22.11个月,基于影像学评估)。
  • 疗效分析纳入71例基线有可测量病灶且随访至少6个月的患者。

主要发现

  • 确认的客观缓解率为42.3%(95%CI 30.6%-54.6%),其中完全缓解9例(12.7%),部分缓解21例(29.6%)。
  • 中位缓解持续时间未达到,6个月和12个月维持缓解的估计概率分别为96.4%和76.8%。
  • 最常见的≥3级治疗相关不良事件为贫血(3/104,2.9%)、结肠炎(2/104,1.9%)和腹泻(2/104,1.9%)。

关键数值与推荐

  • 给药方案:多塔利单抗500 mg静脉注射每3周一次共4剂,之后1000 mg每6周一次,直至疾病进展、治疗中止或退出。
  • 主要终点为盲法独立中心审查根据RECIST 1.1评估的客观缓解率和缓解持续时间。

临床怎么用

  • 对于经铂类化疗后的错配修复缺陷子宫内膜癌患者,多塔利单抗可作为具有持久缓解潜力的治疗选择。
  • 治疗期间需监测贫血、结肠炎和腹泻等不良事件。

局限性

  • 本研究为非随机、单组、开放标签设计,未设对照组。
  • 疗效分析仅纳入71例基线有可测量病灶且随访至少6个月的患者,样本量有限。
  • 中位随访时间较短(11.2个月),中位缓解持续时间尚未达到。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Deficient mismatch mutation repair mechanisms may sensitize endometrial cancers to anti-programmed death 1 (PD-1) therapies. Dostarlimab (TSR-042) is an investigational anti-PD-1 antibody that binds with high affinity to the PD-1 receptor. OBJECTIVE: To assess the antitumor activity and safety of dostarlimab for patients with deficient mismatch repair endometrial cancer. DESIGN, SETTING, AND PARTICIPANTS: This ongoing, open-label, single-group, multicenter study began part 1 on March 7, 2016, and began enrolling patients with deficient mismatch mutation repair endometrial cancer on May 8, 2017. Median follow-up was 11.2 months (range, 0.03 [ongoing] to 22.11 [ongoing] months; based on radiological assessments). Statistical analysis was performed July 8 to August 9, 2019. INTERVENTIONS: Patients received 500 mg of dostarlimab intravenously every 3 weeks for 4 doses, then 1000 mg every 6 weeks until disease progression, treatment discontinuation, or withdrawal. MAIN OUTCOMES AND MEASURES: The primary end point was objective response rate and duration of response by blinded independent central review using Response Evaluation Criteria in Solid Tumors, version 1.1. RESULTS: As of the data cutoff, 104 women (median age, 64.0 years [range, 38-80 years]) with deficient mismatch mutation repair endometrial cancers were enrolled and treated with dostarlimab. Of these, 71 had measurable disease at baseline and at 6 months or more of follow-up and were included in the analysis. There was a confirmed response in 30 patients (objective response rate, 42.3%; 95% CI, 30.6%-54.6%); 9 patients (12.7%) had a confirmed complete response, and 21 patients (29.6%) had a confirmed partial response. Responses were durable; the median duration of response was not reached (median follow-up was 11.2 months). The estimated likelihood of maintaining a response was 96.4% at 6 months and 76.8% at 12 months. Anemia (3 of 104 [2.9%]), colitis (2 of 104 [1.9%]), and diarrhea (2 of 104 [1.9%]) were the most common grade 3 or higher treatment-related adverse events. CONCLUSIONS AND RELEVANCE: In this nonrandomized trial, dostarlimab was associated with clinically meaningful and durable antitumor activity with an acceptable safety profile for patients with deficient mismatch mutation repair endometrial cancers after prior platinum-based chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02715284.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Oaknin A, Tinker AV, Gilbert L, et al. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial. JAMA Oncol. 2020. PMID: 33001143. doi:10.1001/jamaoncol.2020.4515

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。